The Kwon Research Group investigates polymeric nanotechnology to formulate, target, and enhance properties of anticancer and antifibrotic drugs. Polymeric nanoparticles and polymeric conjugates prolong circulation in blood, enhance potency, and reduce toxicity of potent yet toxic anticancer drugs and biologics. Our aim is to devise safe and effective nanomedicines for cancer and fibrosis that can be translated into humans for clinical trials, hopefully saving lives.
The objective of this focus area is to formulate anticancer nanoparticles to lower toxicity and enhance potency of a repertoire of poorly water-soluble anticancer drugs. We focus on a novel prodrug strategy for polymeric nanoparticles, seeking delayed-release and enhanced delivery into solid tumors. See an example of our work in this area here.
04/01/2021 – 03/31/2025
The objective of this focus area is to investigate water-soluble PEGylated peptides for the imaging and treatment of breast cancer, focusing on targeting the extracellular matrix of solid tumors. See an example of our work in this area here.
06/01/2021 – 05/31/2023
The objective of this focus area is to investigate water-soluble PEGylated peptides for the imaging and treatment of pulmonary fibrosis, focusing on disruption of fibronectin fibrillogenesis and collagen deposition. See an example of our work in this area here.
DoD PRMR Program – Submitted
07/01/2022 – 06/30/2026
Jorge Heller Journal of Controlled Release/CRS Outstanding Paper Award
American Association of Colleges of Pharmacy (AACP) Faculty New Investigator Award
NIH FIRST Award
CRS Young Investigator Research Achievement Award
Invited Lecturer, 15th Nisshin Engineering Particle Technology International Seminar, Awaji, Japan
Fellow of AAPS
Distinguished Lecturer, Shizuoka DDS Conference, The Nagai Foundation, Japan
20th PhD student (Hyunah Cho)
Selection of Co-D Therapeutics for Emerging Company Showcase by BioForward, WI
Highly Cited Researcher, Thomson Reuters, Pharmacology & Toxicology
Orphan drug designation for Triolimus, 3-drug nanomedicine for the treatment of angiosarcoma
AAPS PharmSciTech Outstanding Manuscript Award
Founding of Wisconsin Center for Nanobiosystems (WisCNano)
Paclitaxel prodrug enters NCL’s Laboratory Assay Cascade Characterization and Testing Program
Editorial Board, Pharmaceutics